Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19): a perspective, double-blind, placebo, randomised controlled trial
- Conditions
- novel coronavirus pneumonia (NCP)
- Registration Number
- ITMCTR2000002964
- Lead Sponsor
- Zhejiang Chinese Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
(1) Patients who meet the diagnostic criteria of the common type of confirmed cases (the initial stage of clinical treatment of traditional Chinese medicine) or the severe cases of confirmed cases (the middle stage of clinical treatment of traditional Chinese medicine);
(2) The cases of common type (the initial stage of clinical treatment of traditional Chinese medicine) belong to the type of cold-dampness stagnant lung;
(3) The confirmed cases were severe (in the middle stage of clinical treatment of traditional Chinese medicine).
(4) The patients knew and agreed to participate in this study.
(1) The critically ill patients in the diagnosis and treatment program of pneumonia with new coronavirus infection issued by the National Health Commission;
(2) It is not suitable for patients who take traditional Chinese medicine decoction;
(3) Those with other serious organ diseases or mental diseases;
(4) Those who are allergic to or have contraindications to the drugs involved in the study scheme.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method